Alan P. Venook, MD
In metastatic colorectal cancer, the anatomic location of the tumor within the colon appears to make a difference in overall survival as well as response to pivotal treatments, according to a retrospective analysis of the pivotal CALGB/SWOG 80405 (Alliance) trial.1...!-->!-->
Deborah Schrag, MD, MPH
Deborah Schrag, MD, MPH, Professor of Medicine at Harvard Medical School, Boston, and an oncologist at Dana-Farber Cancer Institute, commented on the findings for The ASCO Post.
She said the inferior survival of patients with right-sided tumors “is almost certainly ...!-->!-->
We have taken on some tough challenges over the past decade, and I’m extremely proud of the organization for not shying away from tackling important issues such as the value of cancer care; launching the TAPUR study, ASCO’s first clinical trial; and creation of CancerLinQ.!-->!-->— Allen ...
Julie M. Vose, MD, MBA, FASCO 2015–2016
Peter Paul Yu, MD, FACP, FASCO 2014–2015
Clifford A. Hudis, MD,
Sandra M. Swain,
Michael P. Link,
George W. Sledge, Jr,
This is an exciting time to be an oncologist. I often say I wish I were 30 again and just starting out in my oncology career. Never before have we had such sophisticated technology for evaluation of the tumor or such a potent arsenal of targeted and effective therapies to treat cancer. Further, the ...
With new immunotherapies available for the treatment of advanced melanoma, an important question is how best to combine and sequence them. Long-term follow-up from the KEYNOTE-001 trial suggests that pembrolizumab (Keytruda) can improve survival in newly diagnosed patients and in those treated...
Michele Cavo, MD
Upfront autologous stem cell transplant remains the standard of care in patients with newly diagnosed multiple myeloma, even in the era of novel agents, according to a phase III study of the European Myeloma Network.1 “Our findings show that autologous stem cell transplant ...!-->!-->
Shaji K. Kumar, MD
Sergio A. Giralt, MD
Two experts in multiple myeloma commented on the EMN02/HO95 MM trial for The ASCO Post: Shaji K. Kumar, MD, Professor of Hematology at the Mayo Clinic, Rochester; and Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at ...!-->!-->!-->!-->
Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the research, industry, regulatory, and advocacy communities convened to debate the topic. The ASCO Post was ...
The prognostic significance of pathologic complete response after neoadjuvant chemotherapy remains unclear, particularly for hormone receptor–positive and HER2-positive breast cancer, where adjuvant therapy after surgery could also have an impact on survival....!-->!-->— Laura Spring, MD
With the recent explosion in immunotherapies for advanced melanoma and other tumors, all eyes are on how best to sequence or combine these therapies. Initial reports of overall survival from the phase II randomized CheckMate 069 trial suggest that the combination of ipilimumab (Yervoy, an...
“When we treat our patients, overall survival is the gold standard. We are all waiting for phase III overall survival data from CheckMate 067,” said formal discussant Padmanee Sharma, MD, PhD, Professor; Scientific Director of the Immunotherapy Platform; and Co-Director of the Parker...!-->!-->
The American Association for Cancer Research (AACR) congratulates its 10 members who have been elected to the National Academy of Sciences (NAS), in recognition of distinguished and continuing achievements in original research. The Academy elected a total of 84 new members and 21 foreign associates ...
William G. Kaelin, Jr, MD
William G. Kaelin, Jr, MD, Chair of the Executive Committee for Research at Dana-Farber Cancer Institute, received the 10th annual Princess Takamatsu Award for “novel and significant work” in cancer from the American Association for Cancer Research (AACR).
On May 17, 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the programmed cell death protein 1 (PD‑1) inhibitor, nivolumab (Opdivo), for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem...
In 1996, the National Comprehensive Cancer Network (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), covering eight tumor types. The NCCN Guidelines® are now published for more than 60 tumor types and topics. Some of the key updates for 2016 were...
We found that 11.4% [of specimens] actually had mixed hepatocellular carcinoma–cholangiocarcinomas. Not much is known about them. The patients were treated as if they had liver cancer, since there is no protocol for the mixed entity.— Varun Kapur, MD
This year’s Annual Meeting of the American Association for Cancer Research (AACR) featured outstanding research in the field of cancer, as well as an inspiring talk by Vice President Joe Biden (see the May 10 issue of The ASCO Post). Here are some summaries of studies that warrant attention; they...
The American Association for Cancer Research (AACR) has announced its 11 newly elected Fellows of the AACR Academy.
The AACR Academy serves to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. All...
Crizotinib (Xalkori) achieved overall and durable responses in advanced inoperable papillary renal cell carcinoma type 1 characterized by somatic MET mutations, according to an investigator-initiated trial conducted by the European Organization for Research and Treatment of Cancer (EORTC).1
It is reasonable to move forward and use crizotinib in this group of patients (MET-positive patients with papillary renal cell carcinoma type 1).— Mayer Fishman, MD, PhD
“This was a difficult study to conduct. It required 13 centers in 8 countries over 3 years to recruit these...!-->!-->
Entrectinib, a potent investigational tyrosine kinase inhibitor, exhibited promising clinical activity in a pooled analysis of two phase I trials of patients with solid metastatic tumors that harbored any of five specific genetic rearrangements involving NTRK1, NTRK2, NTRK3, ROS1, or ALK.
These studies are the product of many decades of sophisticated research.… Now we are seeing a ‘glory’ moment where patients can benefit from this extensive research.— Louis M. Weiner, MD
“These gene fusions that drive malignant processes in certain cancers are good targets for...!-->!-->
Vice President Joe Biden
In the fall of 2015, Vice President Joe Biden called for a “moonshot” to cure cancer. In his final State of the Union Address on January 12, 2016, President Barack Obama reemphasized that goal, stating, “Let’s make America the country that cures cancer once and for ...!-->!-->
Earlier this month, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the investigational MEK1/2 inhibitor selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer.
Selumetinib inhibits the MEK...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
On April 11, 2016, venetoclax (Venclexta) was approved for...
The U.S. Food and Drug Administration (FDA) is continuing its efforts to expedite oncology-hematology drug approvals. As of May 15, 2016, FDA has approved the following agents since January of this year.
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met April 12 to consider a New Drug Application by Clovis Oncology for rociletinib, an investigational therapy for epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC) in patients...
Half of the young women presenting to an academic surgical breast practice would qualify for mammography screening starting at age 40. According to the newly updated guidelines, these young at-risk women may be missed, researchers reported at the 2016 American Society of Breast Surgeons (ASBS)...
Mahmoud El-Tamer, MD
Mahmoud El-Tamer, MD, a breast surgeon at Memorial Sloan Kettering Cancer Center, New York, who moderated the session where the results were presented, pointed out that although the results were provocative, the selection of patients was “biased,” as they had already...!-->!-->
Susan Love, MD, MBA
The “collateral damage” of cancer treatment is a topic that is familiar to Susan Love, MD, MBA. As a breast cancer surgeon and chief visionary officer of Dr. Susan Love Research Foundation, she has learned much about the consequences of cancer treatment. But she came by ...!-->!-->
Oliver Bogler, PhD
Three and a half years ago, Oliver Bogler, PhD, a cancer biologist and Senior Vice President of Academic Affairs at the University of Texas MD Anderson Cancer Center, saw his personal and professional worlds collide. He received a cancer diagnosis—one that mirrored his...!-->!-->
Andrew Bindman, MD
Andrew Bindman, MD, a primary care physician with federal and state health policy experience who has practiced, taught, and conducted health services research at San Francisco General Hospital, has been named the new Director of the Agency for Healthcare Research and...!-->!-->
Lifang Hou, MD, PhD
Lifang Hou, MD, PhD, has been appointed Director of Global Health for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Hou brings her extensive experience in identifying risk factors and molecular biomarkers predictive of cancer risk and...!-->!-->
To our knowledge, neratinib taken for 12 months is the first therapeutic intervention to significantly improve invasive disease–free survival beyond trastuzumab-based adjuvant therapy in women with HER2-positive early-stage breast cancer.— Arlene Chan, MD, and colleagues
In the ...!-->!-->
Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the...
In the phase III GERCOR LAP07 trial reported by Pascal Hammel, MD, of Beaujon Hospital, Clichy, France, and colleagues in JAMA, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine...
On Monday, April 11, ASCO released a policy statement calling on member oncologists to help lead a push for all adolescents and young adults to be vaccinated against cervical and other cancer.
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of...
Next month, more than 30,000 oncology professionals will gather in Chicago for the 2016 ASCO Annual Meeting. This year’s theme, “Collective Wisdom: The Future of Patient-Centered Care and Research,” highlights the value of the combined knowledge of the global oncology community, spanning across...
In the United States, only 36% of girls and 14% of boys ages 11 to 13 are fully vaccinated against HPV. Last month, ASCO addressed this issue in a statement urging aggressive efforts to increase vaccination and prevent cancer. Your patients can quickly learn some facts about this underused form of...
Matthew I. Milowsky, MD
Cheryl T. Lee, MD
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical...!-->!-->!-->!-->
The bottom line is that these two groups have produced a commonsense, evidence-based manifesto that guides clinicians to provide the correct treatment of advanced bladder cancer, based on evidence rather than rhetoric and hype.— Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
These results provide a strong rationale against the use of these drugs for high-risk kidney cancer in the adjuvant setting and suggest that the biology of cancer recurrence might be independent of angiogenesis.— Naomi B. Haas, MD, and colleagues
In the phase III ECOG-ACRIN...!-->!-->
The reasons for low tolerability in the adjuvant setting may relate to there being less disease present and the agents’ not exerting an antiangiogenic effect on micrometastases. In theory, patients without metastatic disease may also be less tolerant of the side effects of these agents...!-->!-->
Al B. Benson III, MD
Al B. Benson III, MD, Associate Director for Cooperative Groups at the Lurie Cancer Center, has been elected President of the National Patient Advocate Foundation’s (NPAF) Executive Board. An oncologist and Professor of Medicine in the Division of Hematology/Oncology...!-->!-->
Suresh Senan, MRCP, FRCR, PhD
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced the 2016 Heine H. Hansen (HHH) Award recipient: Suresh Senan, MRCP, FRCR, PhD. The award was presented at the European Lung...!-->!-->
Atezolizumab showed durable activity and good tolerability in this patient population. Increased levels of PD-L1 expression on immune cells were associated with increased response.— Jonathan E. Rosenberg, MD, and colleagues
In a phase II trial reported in The Lancet, Jonathan...!-->!-->
This new class of immunotherapeutic antibodies, led by atezolizumab, offers patients with metastatic or locally advanced transitional cell carcinoma hope for nontoxic, durable responses.— Nicholas J. Vogelzang, MD
The recent study by Rosenberg et al in The Lancet—summarized in...!-->!-->
On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima) in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment of...
Our results support that these associations are broadly generalizable to different populations, including people who are overweight or obese or those with a history of smoking. Health-care professionals counseling inactive adults should promote physical activity as a component of a...!-->!-->
Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eribulin could be a treatment option for advanced soft-tissue sarcoma.— Patrick Schöffski, MD, and colleagues
In a phase III trial reported in...!-->!-->
Eribulin appears to have a unique mechanism of action, with data suggesting its benefits are due less to direct cytotoxic effects and more to changes in the tumor microenvironment or malignant cells.— Margaret von Mehren, MD
Sarcoma therapy is a challenge for oncologists....!-->!-->
Patricia Flatley Brennan, RN, PhD
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has named Patricia Flatley Brennan, RN, PhD, Director of the National Library of Medicine (NLM). The NLM is the world’s largest biomedical library and the producer of digital...!-->!-->
Brian Czerniecki, MD, PhD
Moffitt Cancer Center has announced that Brian Czerniecki, MD, PhD, has joined the faculty and will serve as the Chair and a member of the Department of Breast Oncology.
Dr. Czerniecki is recognized for his contribution to the development of sentinel lymph node...!-->!-->
Robert S. Langer, ScD
The American Association for Cancer Research (AACR) honored Robert S. Langer, ScD, with the 2016 AACR-Irving Weinstein Foundation Distinguished Lectureship at the AACR Annual Meeting 2016, held in New Orleans, on April 16–20.
The AACR-Irving Weinstein Foundation...!-->!-->
Peter Paul Yu, MD, FACP, FASCO
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for...!-->!-->
Technology entrepreneur Larry Ellison has donated $200 million to establish the Lawrence J. Ellison Institute for Transformative Medicine of the University of Southern California (USC), a new center in Los Angeles that will combine interdisciplinary research with the holistic prevention and...
Sam S. Chang, MD
The American Urological Association (AUA), together with the Society for Urologic Oncology (SUO), has released a new clinical practice guideline on non–muscle-invasive bladder cancer. This new document outlines guidance on a variety of topics, including diagnosis and...!-->!-->
Paul Celano, MD, FACP
ASCO established a State Affiliate Council in 2012 consisting of representatives from each of the Society’s 48 state or regional oncology societies. The Council met on April 21–22 at ASCO headquarters in Alexandria, Virginia.
The ASCO Post talked with Paul Celano,...!-->!-->
The lack of an adequately trained workforce of surgical oncologists can be a major detriment in efforts to address the rising global cancer burden, according to two leading international surgical oncology societies.
In two jointly published reports,1,2 the Society of Surgical Oncology (SSO) and...
Title: A Physician’s Guide to Pain Symptom Management in Cancer Patients, 3rd Edition
Author: Janet L. Abrahm, MD
Publisher: Johns Hopkins University Press
Publication date: December 2014
Price: $39.95; paperback, 664 pages
Despite growing awareness and the...!-->!-->
Title: Managing Prostate Cancer: A Guide for Living Better
Author: Andrew J. Roth, MD
Publisher: Oxford University Press
Publication date: November 2015
Price: $21.95; hardcover, 368 pages
This year, an estimated 180,890 men in the United States will be diagnosed with...!-->!-->
The numbers are difficult to fathom. According to a report by the United Nations High Commissioner for Refugees (UNHCR), in 2015, over 60 million people worldwide were forcibly displaced as a result of conflict, persecution, generalized violence, or human rights violations.1 Over 9 million of those ...
Mackenzi Pergolotti, PhD
Adults with cancer are at high risk for functional limitations that would negatively affect their quality of life. Occupational therapy offers a range of supportive services, with the specific goal of helping these patients engage in life as independently as...!-->!-->
Stuart M. Lichtman, MD
Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer...
Jamie H. Von Roenn, MD
Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD. Dr. Von Roenn is ASCO’s Senior Director of Education, Science, and Professional ...
Dying: A Transition
The night before Julius Caesar was assassinated, he...
Michael Silbermann, DMD, PhD
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to...!-->!-->
The American Association for Cancer Research (AACR) honored Mary “Dicey” Jackson Scroggins with the 2016 AACR Distinguished Public Service Award as part of the Opening Ceremony for the AACR Annual Meeting 2016, held in New Orleans on April 16–20, 2016. She was recognized for her long-standing...
Hagop Kantarjian, MD
Imatinib mesylate (Gleevec), a Bcr-Abl tyrosine kinase inhibitor, is approved therapy for chronic myeloid leukemia (CML) in the United States. Imatinib is a miraculous drug that results in a normal functional lifespan in most patients with CML who can afford and...
David L. Porter, MD
Antoni Ribas, MD, PhD
Suresh S. Ramalingam, MD
More than 100 years after William B. Coley, MD, used bacterial toxins to goad the immune system into recognizing cancer cells as foreign to the body and mount an immune response to go after and kill ...
Syed A. Abutalib, MD
In this installment of Hematology Expert Review, I will summarize five studies from the recent literature addressing important questions about leukemias and their treatment, anticoagulant therapy with the new agent defibrotide (Defitelio), and the use of antilymphocyte ...!-->!-->
When Evelyn H. Lauder was diagnosed with breast cancer in 1989, she became a vocal spokesperson for women’s health, and in 1993, along with Larry Norton, MD, now Deputy Physician-in-Chief for Breast Cancer Programs and Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan...
Lymphoma: State-of-the-Art in Biology Therapy, and Patient Care
May 13-14 • New York, New York
For more information:
CancerLinQ LLC announced on April 21 that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology platform that will harness big data analytics to help oncologists rapidly improve high-quality ...
Vincent Lo Re, MD, MSCE, Assistant Professor of Medicine in the Division of Infectious Diseases and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, and Amy Justice, MD, PhD, Professor of General Medicine and Public Health at Yale School of Public Health, have been ...
When Waun Ki Hong, MD, and his pregnant wife, Mihwa, made the journey from Korea to Manhattan in 1970, he had just $451 in his wallet, and the only job he could get was as an intern in Bronx-Lebanon Hospital Center, a community hospital in the Bronx. The work was grueling—24-hour shifts every 2...
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, of Memorial Sloan Kettering Cancer Center, New York.
Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy...
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
On April 25, 2016, a tablet formulation of cabozantinib...
The Big Casino
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
“There are a lot of myths around new and emerging tobacco products, including e-cigarettes, and unfortunately, the biggest misconception is that these products are fairly or entirely harmless and risk-free,” Alexander V. Prokhorov, MD, PhD, said in an interview with The ASCO Post about a new...
Elderly men had a significant increase in the risk of noncancer hospitalizations following the diagnosis of prostate cancer, according to a population-based retrospective cohort study conducted by Amit D. Raval, PhD, and colleagues at West Virginia University, Morgantown. Results were published in...
Relatives of patients with carcinoma of unknown primary are at increased risk of developing this type of cancer themselves and several other malignant neoplasms, including lung, pancreatic, and colon cancers; non-Hodgkin lymphoma; and myeloma, according to a study published in JAMA Oncology. “Some...
William J. Gradishar, MD, FACP, has been appointed Deputy Director for the Clinical Network of the Robert H. Lurie Comprehensive Cancer Center Network of Northwestern University. In this new role, Dr. Gradishar will oversee the coordination of clinical cancer services within Lurie Cancer Center’s...
The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, patients with cancer.